All articles tagged with #parkinsons disease
After Novo Nordisk shuttered its cell-therapy unit, Cellular Intelligence hired neurologist Nuno Mendonça to perform due diligence on Novo’s Parkinson’s stem-cell program. The data trail—drawn from Lund University research and Nature Medicine–published work on dopamine-neuron therapies—appears to have driven the AI-driven assessment that led the firm to pursue Novo’s asset.
A Texas A&M study used Theiler's murine encephalomyelitis virus (TMEV) in mice to model Parkinson's-like neurodegeneration. The virus infected dopamine-producing neurons and caused motor deficits that persisted after the virus was cleared, suggesting viruses could contribute to Parkinson's risk alongside genetic or environmental factors. This new viral model offers a tool to study disease progression and etiology, complementing genetic or toxin-based models, though TMEV itself does not infect humans.
Hundreds of studies suggest daily coffee may protect against liver disease, lower the risk of Type 2 diabetes, and reduce Parkinson’s disease risk, with compounds like chlorogenic acid aiding insulin sensitivity and liver protection.
A UCLA-led study found long-term residential exposure to the pesticide chlorpyrifos is linked to more than a 2.5-fold increase in Parkinson’s disease risk. Lab experiments in mice and zebrafish suggest chlorpyrifos damages dopamine neurons by disrupting autophagy, offering insight into the disease mechanism and potential therapeutic targets and underscoring the need for monitoring exposed individuals.
Scientists at Baylor College of Medicine report that tubulin can prevent Tau and alpha-synuclein from forming toxic aggregates in brain cells by redirecting these proteins toward healthy microtubule functions, offering a potential therapeutic strategy that boosts tubulin levels rather than halting droplet formation to preserve normal neuronal activity.
UCSF researchers developed a closed-loop adaptive deep brain stimulation system that detects step-specific brain signals and automatically modulates stimulation within milliseconds, synchronizing with walking to improve gait symmetry and reduce falls in five Parkinson’s patients—evidence supporting a shift from fixed stimulation to behavior-responsive neuromodulation with potential broader applications.
Cheryl Krueger, founder of Cheryl’s Cookies and a Central Ohio entrepreneur, has died. She was widely remembered for her philanthropic work supporting Parkinson’s disease research, education, and cancer-related causes, leaving a lasting local legacy.
AI-native platforms are transforming stem-cell research into predictive engineering, accelerating the design, testing, and manufacturing of living cell therapies. Cellular Intelligence is applying an AI foundation model to Novo Nordisk’s clinical-stage Parkinson’s program to speed development, reduce costs, and produce scalable, personalized treatments, with potential applications to cancer and other diseases.
Parkinson's disease is more than tremors; non-motor symptoms—like loss of smell, REM sleep disorder, constipation, anxiety, depression, cognitive changes and fatigue—can drive daily challenges and may appear years before motor signs, even in Young-Onset Parkinson's under 50. Treatments such as Levodopa, Deep Brain Stimulation, and focused ultrasound help manage symptoms, while research on disease-modifying drugs, gene therapy, and biomarkers progresses, supported by the Michael J. Fox Foundation's more than $2.5 billion raised. Local support groups and educational events aid patients and caregivers; early diagnosis and proactive management are key—consult a provider and visit mountain.commonspirit.org for more information.
A U.S. Air Force veteran and anesthesiologist diagnosed with Parkinson's at 46 embraces aerobic exercise as a core strategy—cycling at 75 rpm for 30–40 minutes, three times weekly—which studies suggest can slow disease progression. Her progression from tremor to Ironman competition and ongoing advocacy illustrates how an exercise-focused approach can restore a sense of control and purpose for people living with Parkinson's.
Public Health Watch links rising Parkinson’s disease risk in the Rio Grande Valley to long-term pesticide exposure, including paraquat drift affecting farmworkers and nearby residents; researchers report brain differences in exposed individuals, while advocates press the EPA and states to tighten safety rules and pursue bans amid limited access to movement-disorder specialists in the region.
Vermont becomes the first U.S. state to ban the herbicide paraquat, citing NIH-linked research that exposure raises Parkinson’s disease risk; the law takes effect on November 1 but allows state regulators to issue special permits through December 31, 2030 for use on certain fruit crops. It requires annual reporting of paraquat use and funds a state study on alternatives. While some lawmakers worry about farmers’ competitiveness, supporters say the health risks justify action, and other states are weighing similar bans amid ongoing lawsuits against the chemical.
Julie Andrews, 90, recorded a rare video message to kick off the World Parkinson's Congress, expressing support for finding a cure and urging the Parkinson's community to stay hopeful.
A California woman recounts moving her 78-year-old mother with Parkinson’s into their home to avoid a costly assisted-living facility, only to face intense daily caregiving demands, constant interruptions during work, safety risks from stairs and a large dog, and financial strain. After escalating stress, they moved her to a smaller, more communal facility with in-home support and, eventually, hospice, which provided better care and allowed the family to regain balance and quality time together.
Biogen and Denali terminated BIIB122 (DNL151), a LRRK2 inhibitor for idiopathic Parkinson’s, after a phase 2b trial failed to meet its primary endpoint despite strong target engagement (about 90% peripheral LRRK2 inhibition and a ~30% CSF biomarker decrease). The decision ends the idiopathic program, though Denali will continue a phase 2a trial in LRRK2-associated Parkinson’s, and the deal’s upfront cost ($400 million in 2020) and earlier phase 3 cutbacks underscore the challenge of translating target activity into clinical benefit in Parkinson’s disease.